2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ezzati M Lopez AD Rodgers A Murray CJL . Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Geneva: World Health Organization, 2004.
World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization, 2011.
Mistry H Morris S Dyer M Kotseva K Wood D Buxton M . Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach. BMJ Open 2012 Oct 11;2. pii: e001029.
Nichols M Townsend N Luengo-Fernandez R Leal J Gray A Scarborough P Rayner M . European Cardiovascular Disease Statistics, 2012. Brussels: European Heart Network, 2012.
O'Keeffe C Kabir Z O'Flaherty M Walton J Capewell S Perry IJ . Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland. BMJ Open 2013;3. pii: e002837.
National Institute for Health and Care Excellence. NICE Public Health Guidance 25. June 2010. https://www.nice.org.uk/guidance/ph25 .
Knopfholz, 2014, Validation of the Friedewald formula in patients with metabolic syndrome, Cholesterol, 2014, 261878, 10.1155/2014/261878
National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Institute for Health and Care Excellence, 2014.
Sabatine, 2015, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events, N Engl J Med, 727, 1500, 10.1056/NEJMoa1500858
Whitfield, 2014, Genetic insights into cardiometabolic risk factors, Clin Biochem Rev, 35, 15
Eckel RH Jakicic JM Ard JD de Jesus JM Houston Miller N Hubbard VS Lee IM Lichtenstein AH Loria CM Millen BE Nonas CA Sacks FM Smith SC Jr Svetkey LP Wadden TA Yanovski SZ Kendall KA Morgan LC Trisolini MG Velasco G Wnek J Anderson JL Halperin JL Albert NM Bozkurt B Brindis RG Curtis LH DeMets D Hochman JS Kovacs RJ Ohman EM Pressler SJ Sellke FW Shen WK Smith SC Jr Tomaselli GF . 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S76–S99.
Mozaffarian, 2009, Health effects of trans-fatty acids: experimental and observational evidence, Eur J Clin Nutr, 63, S5, 10.1038/sj.ejcn.1602973
Brown, 1999, Cholesterol-lowering effects of dietary fiber: a meta-analysis, Am J Clin Nutr, 69, 30, 10.1093/ajcn/69.1.30
Dattilo, 1992, Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis, Am J Clin Nutr, 56, 320, 10.1093/ajcn/56.2.320
Keys, 1984, Serum cholesterol response to dietary cholesterol, Am J Clin Nutr, 40, 351, 10.1093/ajcn/40.2.351
Shaw, 2006, Exercise for overweight or obesity, Cochrane Database Syst Rev, 4, CD003817
Yu-Poth, 1999, Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis, Am J Clin Nutr, 69, 632, 10.1093/ajcn/69.4.632
Harris, 1997, n-3 fatty acids and serum lipoproteins: human studies, Am J Clin Nutr, 65, 1645S, 10.1093/ajcn/65.5.1645S
Poli, 2008, Non-pharmacological control of plasma cholesterol levels, Nutr Metab Cardiovasc Dis, 18, S1, 10.1016/j.numecd.2007.10.004
Mensink, 2003, Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials, Am J Clin Nutr, 77, 1146, 10.1093/ajcn/77.5.1146
Liu, 2001, Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women, Am J Clin Nutr, 73, 560, 10.1093/ajcn/73.3.560
Taylor, 2013, Statins for the primary prevention of cardiovascular disease, Cochrane Database Syst Rev, 1, CD004816
McGuinness, 2014, Statins for the treatment of dementia, Cochrane Database Syst Rev, 7, CD007514
Eslami, 2013, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, Cochrane Database Syst Rev, 12, CD008623
Li, 2011, Statins for primary prevention of venous thromboembolism, Cochrane Database Syst Rev, 12, CD008203
Raval, 2011, Statins for women with polycystic ovary syndrome not actively trying to conceive, Cochrane Database Syst Rev, 10, CD008565
Palmer, 2014, HMG CoA reductase inhibitors (statins) for kidney transplant recipients, Cochrane Database Syst Rev, 1, CD005019
Cziraky MJ Willey VJ McKenney JM Kamat SA Fisher MD Guyton JR Jacobson TA Davidson MH . Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006;97(8A):61C–68C.
Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785–794 e10.
Abumweis SS Barake R Jones PJ . Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52. ISSN 1654-661X. Available at http://www.foodandnutritionresearch.net/index.php/fnr/article/view/1811 .
Tyroler, 1984, Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial, Am J Cardiol, 54, 14C, 10.1016/0002-9149(84)90851-8
Keene D Price C Shun-Shin MJ Francis DP . Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014;349:g4379.
Davidson MH Armani A McKenney JM Jacobson TA . Safety considerations with fibrate therapy. Am J Cardiol 2007;99(6A):3C–18C.
Herrmann, 2012, Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study, Clin Chem Lab Med, 50, 2213, 10.1515/cclm-2012-0078
Brown BG Zhao XQ . Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008;101(8A):58B–62B.
World Health Organization. Human Genetics Programme. Familial hypercholesterolemia: report of a second WHO consultation. WHO/HGN/FH/Cons/992. Geneva: World Health Organization, 1999.
Donahoe SM Stewart GC McCabe CH Mohanavelu S Murphy SA Cannon CP Antman EM . Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298:765–775.
Palmer, 2014, HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis, Cochrane Database Syst Rev, 5, CD007784
Tonelli, 2014, Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline, Ann Intern Med, 160, 182, 10.7326/M13-2453
Navaneethan, 2009, HMG CoA reductase inhibitors (statins) for kidney transplant recipients, Cochrane Database Syst Rev, 2, CD005019
Aung, 2007, Lipid-lowering for peripheral arterial disease of the lower limb, Cochrane Database Syst Rev, 4, CD000123
Islam, 2012, Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis, HIV Med, 13, 453, 10.1111/j.1468-1293.2012.00996.x
Godin O Etain B Henry C Bougerol T Courtet P Mayliss L Passerieux C Azorin JM Kahn JP Gard S Costagliola D Leboyer M . Metabolic syndrome in a French cohort of patients with bipolar disorder: results from the FACE-BD cohort. J Clin Psychiatry 2014;75:1078–1085; quiz 1085.
McGinnis, 2009, Statin adherence and mortality in patients enrolled in a secondary prevention program, Am J Manag Care, 15, 689
Hinchcliffe A . Patient Adherence to Treatment with Statins for the Prevention of Cardiovascular Disease. Cardiff: Public Health Wales NHS Trust, 2011.
Blackburn, 2005, Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study, Can J Cardiol, 21, 485
Aubert, 2010, Is there a relationship between early statin compliance and a reduction in healthcare utilization, Am J Manag Care, 16, 459
Abramson JD Rosenberg HG Jewell N Wright JM . Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123.
Huffman M Taylor F Ebrahim S . Huffman and colleagues' response to Abramson and colleagues' article on statins in low risk people. BMJ 2014;348:g1520.
Becker, 1974, The Health Belief Model and personal health behaviour, Health Educ Monogr, 2, 324, 10.1177/109019817400200407
Jackson, 2014, Applying COM-B to medication adherence, Eur Health Psychol, 16, 7
Harrison, 2013, Primary nonadherence to statin therapy: patients' perceptions, Am J Manag Care, 19, e133
Rubak, 2005, Motivational interviewing: a systematic review and meta-analysis, Br J Gen Pract, 55, 305
Bandura A . Self-Efficacy: The Exercise of Control. New York: Freeman, 1997.
Schedlbauer, 2010, Interventions to improve adherence to lipid lowering medication, Cochrane Database Syst Rev, 3, CD004371
Nieuwlaat, 2014, Interventions for enhancing medication adherence, Cochrane Database Syst Rev, 11, CD000011
Ryan, 2014, Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews, Cochrane Database Syst Rev, 4, CD007768